Abstract: Chapter 2 Metformin Joseph Timmons and, Joseph Timmons andSearch for more papers by this authorJames Boyle, James BoyleSearch for more papers by this author Joseph Timmons and, Joseph Timmons andSearch for more papers by this authorJames Boyle, James BoyleSearch for more papers by this author Book Editor(s):Miles Fisher, Miles FisherSearch for more papers by this authorGerard A. Mckay, Gerard A. MckaySearch for more papers by this authorAndrea Llano, Andrea LlanoSearch for more papers by this author First published: 27 June 2022 https://doi.org/10.1002/9781119785033.ch2 AboutPDFPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShareShare a linkShare onFacebookTwitterLinked InRedditWechat Abstract Metformin is one of the oldest antidiabetic drugs for the treatment of type 2 diabetes. It remains first line in most international guidelines for people with type 2 diabetes who are unable to maintain target glycaemia with lifestyle measures alone. Metformin works primarily by reducing hepatic gluconeogenesis and sensitising peripheral tissues to the effects of insulin. It is a safe and effective drug with proven cardiovascular benefits. Metformin does not cause weight gain or hypoglycaemia and may be associated with weight loss. While gastrointestinal side effects are common and can limit its use in some people, lactic acidosis is the most important side effect of metformin but is rare. The role of metformin remains central to the management of people with type 2 diabetes, whereas the role of metformin in people with type 1 diabetes and in preventing type 2 diabetes remains uncertain. It is likely that metformin may yet have novel roles in the management and prevention of diabetes and its complications. Diabetes Drug Notes RelatedInformation
Publication Year: 2022
Publication Date: 2022-06-27
Language: en
Type: other
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot